These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29247039)

  • 1. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
    Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
    Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
    Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
    Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
    Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
    Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
    Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
    Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
    Rezende Miranda R; Fu Y; Chen X; Perino J; Cao P; Carpten J; Chen Y; Zhang C
    J Med Chem; 2020 Oct; 63(20):11484-11497. PubMed ID: 33030342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
    Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF19-
    Raja A; Park I; Haq F; Ahn SM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.